3rd October 2018
Coventry, UK, 3rd October 2018 / Medherant, a developer of innovative transdermal drug delivery treatments for pain and CNS diseases, has been awarded a Medic
CPhI awards logo
11th September 2018
Medherant has been shortlisted for the CPhI Pharma Awards in both the Formulation and Drug Delivery Devices categories for its TEPI Patch® technology.
6th June 2018
Transdermal drug delivery systems have been used in different forms since ancient times.
David Davies
7th March 2018
Medherant Ltd, a leader in next-generation transdermal drug delivery, is pleased to announce the appointment of a new senior executive, David Davies, as Head of Development. This appointment marks a significant expansion of the Company’s management team to support the business as it moves into clinical development of its ibuprofen TEPI Patch®.
14th February 2018
There are many problems linked to oral drug administration including first pass metabolism, gastrointestinal tract damage and low levels of drug reaching the target site.
18th December 2017
The Journal of Pharmaceutical Innovation, Springer, has published the research paper 'Transdermal Delivery of Ibuprofen Utilizing a Novel Solvent-Free Pressure-sensitive Adhesive (PSA): TEPI® Technology', a
11th December 2017
Medherant, a leader in next-generation transdermal drug delivery, has raised £3.8 million in its latest funding round. The fundraising was led by majority shareholder Mercia Technologies PLC, with the balance coming from other existing shareholders as well as new private investors. This latest investment will support the company as it progresses its ibuprofen TEPI Patch® into clinical development in early 2018.
17th November 2017
Medherant is delighted to announce they have been awarded the ‘Excellence in Science & Technology Award’ at the Coventry Telegraph Business Awards last night. These Awards are a celebration of companies in Coventry and Warwickshire which have achieved success for themselves, their staff and their customers.
27th September 2017
Coventry, UK, 27th September 2017 / Medherant, a leader in next-generation transdermal drug delivery, has signed an agreement with a Japanese transdermal patc
28th July 2017
Medherant is looking for an experienced CPM to manage its international clinical studies and support the Head of Clinical Development in establishing and maintaining a GCP management system.